Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs).
ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED).
Specifically, the goal of the NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to (1) optimize precise targeting of disease-relevant cell subtypes in aged and degenerating mammalian brains and (2) monitor and/or manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animals models.
To achieve this goal, the NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code.
The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle.
The R33 phase provides up to 3 years of support for implementation activities including hypothesis testing.
ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED).
Specifically, the goal of the NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to (1) optimize precise targeting of disease-relevant cell subtypes in aged and degenerating mammalian brains and (2) monitor and/or manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animals models.
To achieve this goal, the NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code.
The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle.
The R33 phase provides up to 3 years of support for implementation activities including hypothesis testing.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $2,400,000
Office: National Institutes of Health
Estimated Funding: $2,400,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2024-05-16
Application Due Date:
Archive Date:
2024-11-12
Social Entrepreneurship
Spotlight
Partnerships in Social Enterprises Can Increase Social Impact
Chief executive of HCT, Dai Powell, shares the experiences and practical lessons he learned along the way when teaming up with Ealing Community Transport to deliver site transport during the Olympic Park construction.
Learn How to Identify and Avoid Grant Scams
